There is never any certainty, and hence they have stated they...

There is never any certainty, and hence they have stated they would need to perform a separate study specifically powered to achieve efficacy in that subgroup. This is why people do sub-group analyses. To show trends which can be further investigated. However I shouldn't need to tell this to someone with a pharmacology degree.

Secondly, that's false, ESCAPE-NA-1 was given as a single dose, similarly our phase II is a single dose over 10 minutes.The longer-half life and not being affected by thrombolysis are keys here. Peptide based drugs exist and are on the market. ESCAPE-NA-1 has provided invaluable information for AGN, particularly having people on our clinical advisory board that were involved in the running of ESCAPE-NA-1. We are primed to design a phase III study that is best placed to achieve efficacy.